Pylarify meds psma 18 injections | ekhcs
Ended Awarded Last action
- Contract number
- 36C25525F0011
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 15
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $260,228
Award facts
- Contract value 100% obligated
- $260,227.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$139,772 | |
| Original award | $400,000 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging Inc., was awarded a delivery order valued at $260,227.84 by Veterans Integrated Service Network 15 on October 22, 2024, for the supply of PYLARIFY (piflufolastat F-18) radiopharmaceutical injections. This firm fixed-price delivery order carries no set-aside designation and is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract. The contract is scheduled for ultimate completion on October 21, 2025, with performance occurring at the company's manufacturing and distribution facility in North Billerica, Massachusetts. PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for the detection and localization of prostate cancer, providing critical diagnostic capabilities for VA medical centers serving veterans.
This delivery order represents one of numerous procurement transactions through which Progenics supplies radiopharmaceutical products to the Veterans Health Administration across multiple Veterans Integrated Service Networks. The parent company, Lantheus Holdings Inc., holds a substantial Federal Supply Schedule contract valued at approximately $290 million extending through March 31, 2030, which establishes the master vehicle framework enabling efficient procurement of radiopharmaceutical supplies across the VA system and Defense Health Agency. Progenics has received over 150 individual contract awards from federal agencies including the Department of Veterans Affairs, Defense Health Agency, and National Institutes of Health, with contract values historically ranging from approximately $10,000 to over $9 million.
Quick answers
Who was awarded contract 36C25525F0011?
36C25525F0011 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 15 (Veterans Health Administration) on October 22, 2024.
How much is contract 36C25525F0011 worth?
The government has obligated $260,228 on 36C25525F0011.
Is contract 36C25525F0011 an order under another contract?
Yes. 36C25525F0011 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25525F0011 competed?
The extent of competition for 36C25525F0011 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award